BioCentury | Mar 8, 2021
Deals

March 8 Quick Takes: Roivant to acquire Immunovant; plus Lilly-Biolojic, Soleno, Gilead, Genentech and Cara-Vifor

Immunovant Inc. (NASDAQ:IMVT) rose $1.88 (14%) to $15.39 on Monday after the autoimmune company said parent Roivant Sciences Ltd. plans to propose an offer to acquire the 42.5% of outstanding shares of Immunovant that Roivant...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

Launched in 2016, Immune-Onc is part of a growing class of immuno-oncology companies converting myeloid cells from immune-suppressing into tumor-suppressing agents. The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed Advisors...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO...
BioCentury | Jan 22, 2021
Regulation

CAR T Yescarta among new approvals by Japanese regulator

Yescarta became the second approved CAR T therapy in Japan, joining a basket of new approvals by the country’s Ministry of Health, Labour and Welfare. The therapy, developed by Gilead Sciences Inc. (NASDAQ:GILD) and partnered...
BioCentury | Dec 11, 2020
Product Development

CAR Ts make the move to earlier lines of treatment despite access barriers

CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment....
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences Inc. (NASDAQ:EVLO)...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

Roche, Lead Pharma form immunology partnershipDutch biotech Lead Pharma Holding B.V. will collaborate with Roche (SIX:ROG; OTCQX:RHHBY) to develop preclinical small molecules against a single, undisclosed target to treat immune-mediated diseases. Lead will receive €10 million...
BioCentury | Nov 10, 2020
Product Development

Pfizer & Biogen: The good, the bAD and what’s next

COVID-19 vaccine data from Pfizer and BioNTech have set a high bar for what could be a rapid wave of readouts from other companies developing vaccines accelerated by surges in case counts. In the latest...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

Adagrasib readout helps Mirati build war chestResponse rate data in the closely-watched KRAS inhibitor race helped Mirati Therapeutics Inc. (NASDAQ:MRTX) raise $800 million in a follow-on via the sale of 4 million shares at $202...
BioCentury | Sep 17, 2020
Deals

Awaiting dialogue with FDA on GI program, microbiome play Finch looks to autism, HBV with new $90M round

With one pivotal readout in Clostridium difficile already achieved, microbiome company Finch has tapped investors for a $90 million series D round that will fund additional programs, and potentially help...
Items per page:
1 - 10 of 1364
BioCentury | Mar 8, 2021
Deals

March 8 Quick Takes: Roivant to acquire Immunovant; plus Lilly-Biolojic, Soleno, Gilead, Genentech and Cara-Vifor

Immunovant Inc. (NASDAQ:IMVT) rose $1.88 (14%) to $15.39 on Monday after the autoimmune company said parent Roivant Sciences Ltd. plans to propose an offer to acquire the 42.5% of outstanding shares of Immunovant that Roivant...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

Launched in 2016, Immune-Onc is part of a growing class of immuno-oncology companies converting myeloid cells from immune-suppressing into tumor-suppressing agents. The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed Advisors...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO...
BioCentury | Jan 22, 2021
Regulation

CAR T Yescarta among new approvals by Japanese regulator

Yescarta became the second approved CAR T therapy in Japan, joining a basket of new approvals by the country’s Ministry of Health, Labour and Welfare. The therapy, developed by Gilead Sciences Inc. (NASDAQ:GILD) and partnered...
BioCentury | Dec 11, 2020
Product Development

CAR Ts make the move to earlier lines of treatment despite access barriers

CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment....
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences Inc. (NASDAQ:EVLO)...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

Roche, Lead Pharma form immunology partnershipDutch biotech Lead Pharma Holding B.V. will collaborate with Roche (SIX:ROG; OTCQX:RHHBY) to develop preclinical small molecules against a single, undisclosed target to treat immune-mediated diseases. Lead will receive €10 million...
BioCentury | Nov 10, 2020
Product Development

Pfizer & Biogen: The good, the bAD and what’s next

COVID-19 vaccine data from Pfizer and BioNTech have set a high bar for what could be a rapid wave of readouts from other companies developing vaccines accelerated by surges in case counts. In the latest...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

Adagrasib readout helps Mirati build war chestResponse rate data in the closely-watched KRAS inhibitor race helped Mirati Therapeutics Inc. (NASDAQ:MRTX) raise $800 million in a follow-on via the sale of 4 million shares at $202...
BioCentury | Sep 17, 2020
Deals

Awaiting dialogue with FDA on GI program, microbiome play Finch looks to autism, HBV with new $90M round

With one pivotal readout in Clostridium difficile already achieved, microbiome company Finch has tapped investors for a $90 million series D round that will fund additional programs, and potentially help...
Items per page:
1 - 10 of 1364